Legal Representation
Attorney
Robert E. Lee, Jr.
USPTO Deadlines
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 15, 2015 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jun 15, 2015 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Nov 5, 2014 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 4, 2014 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Oct 31, 2014 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 31, 2014 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Apr 18, 2014 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Apr 17, 2014 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Apr 16, 2014 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Mar 24, 2014 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 24, 2014 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Nov 12, 2013 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 17, 2013 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 17, 2013 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 28, 2013 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 11, 2013 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 11, 2013 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 9, 2013 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 6, 2013 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antidepressants
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005